Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Stay updated with the latest weekly cash back credit card deals to maximize your savings. Don't miss these offers!
23,042 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Bitcoin miners start funding AI pivots by borrowing and selling BTC to stay liquid as margins tighten, hash prices fa...
Nvidia stock sank today as investors weighed growth, margins, and AI demand ahead of next week’s earnings. This guide...
Analysts warn that the Social Security funding gap could reach a tipping point in the early 2030s. If policy action s...
As debt pressures mount, Ray Dalio warns the stock market may be flirting with bubble-like extremes seen before the 1...
A Dow industrial stock with a durable moat is grabbing attention as markets bounce. Here’s how patient buyers see a c...
As Micron Technology rides AI-driven memory demand, investors debate a bold forecast. Market models suggest a potenti...
Two fast-casual leaders headline the 2026 investor debate: a Mediterranean newcomer with fast expansion and a Mexican...
A downgrade and AI chip headlines pushed Broadcom stock lower today. Here’s what happened, what it could mean, and pr...
CoreWeave has dropped substantially from its 52-week peak, leaving investors debating whether the bounce is coming or...
A stock with an eye popping yield can grab attention fast. But does the income last as the business navigates headwin...
Amgen's dividend has powered income-focused portfolios for years, but regulatory and pricing challenges raise questio...